Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Basic science

5353 - Landscape of DNA damage response (DDR) genes alterations in the prospective MOSCATO and MATCH R trials


10 Sep 2017


Basic science


Translational Research


Yolla El Dakdouki


Annals of Oncology (2017) 28 (suppl_5): v595-v604. 10.1093/annonc/mdx391


Y. El Dakdouki1, L. Verlingue2, C. Massard3, R. Bahleda4, A. Hollebecque5, L. Mahjoubi2, E. Rouleau6, L. Lacroix7, N. Auger8, J. Scoazec9, E. Solary10, A. Marabelle11, F. André12, J. Soria13, S. Postel-Vinay14

Author affiliations

  • 1 Duertec, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 2 Drug Development Department (ditep), Gustave Roussy, 94805 - Villejuif/FR
  • 3 Early Drug Development Department, Institut de Gustave Roussy, Villejuif/FR
  • 4 Early Drug Development Department, Gustave Roussy, 94805 - Villejuif/FR
  • 5 Drug Development Department (ditep), Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 6 Département De Biologie Et Pathologie Médicales, Gustave ROUSSY, 94805 - VILLEJUIF/FR
  • 7 Bmo, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 8 Laboratoire De Recherche Translationnelle, Gustave Roussy, 94805 - Villejuif/FR
  • 9 Pathology, Gustave Roussy Institute, Villejuif/FR
  • 10 Umr 1170, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 11 Département D’innovation Thérapeutique Et D’essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif/FR
  • 12 Breast Cancer Unit, Department Of Medical Oncology, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 13 Department Of Drug Development, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 14 Départemement D’innovation Thérapeutique Et Des Essais Précoces (ditep), Institut Gustave Roussy, 94800 - Villejuif/FR


Abstract 5353


DDR deficiency is a hallmark of cancer. We aimed at describing in 2 prospective trials run at Gustave Roussy Cancer Campus the molecular and clinical characteristics of patients (pts) harboring DDR gene alterations with special focus on mismatch repair (MMR).


Pts with metastatic solid tumors enrolled in MOSCATO (NCT01566019) and MATCHR (NCT02517892) trials had on-purpose tumor biopsy; molecular profiling was performed using Targeted Next Generation Sequencing (TGS) and Comparative Genomic Hybridization array (CGHa), or Whole Exome Sequencing (WES). Alterations in 46 genes involved in DNA repair were searched. After review by molecular geneticist, pathogenic variants (PV) were defined as variants causing protein truncation (frameshift indels, nonsense or splice site variants) or known to be deleterious missense variants according to databases such as LOVD, BRCAshare and OncoKB. Variants without deleterious prediction were excluded.


Molecular data of 1092 pts of various histologies enrolled between Dec. 2011 and Oct. 2016 was used. Analysis of TGS (N = 1090), CGHa (N = 838) and WES (N = 304) data allowed identifying 156 alterations in 107 pts (9.8%) and 30 DDR genes: 60 PV, 86 variants of unknown pathogenicity (VUP) and 10 focal deletions (CGHa). Most frequent altered pathways were homologous recombination (47 PV, including 30 BRCA1/2 PV and 7 ATM PV in 13 primary sites) and MMR. The 27 pts with 35 MMR and POLE alterations (12 PV, 20 VUP and 3 deletions) had 11 different primary types including most frequently colorectal, genito-urinary and breast. Only one pt was previously known to have Lynch syndrome. Missense PV occurred most frequently in POLE, MLH1, MSH2, PMS1 (2 each), as well as, MSH3 and MLH3 (1 each); 14/27 pts received immunotherapy (IO). Median PFS was 6.5 months with IO and 6.2 months with conventional therapy. Correlation of MMR aberrations with immune infiltrates and outcome (response, PFS and OS) on IO will be presented at the congress time.


DDR genes alterations occur regularly in solid tumors. Systematic analysis of DDR alterations could allow customizing treatment of pts that specifically benefit from IO or DNA repair inhibitors through synthetic lethality.

Clinical trial identification

NCT01566019 and NCT02517892

Legal entity responsible for the study

Gustave Roussy Cancer Campus


Gustave Roussy Cancer Campus.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.